Mary Ellen S. Frustaci

As seen in: Gastrointestinal Endoscopy

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mary Ellen S.

Contact Mary Ellen S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

487 EFFICACY OF ICOTROKINRA, THE FIRST TARGETED ORAL PEPTIDE THAT SELECTIVELY BLOCKS THE INTERLEUKIN-23 RECEPTOR, IN ULCERATIVE COLITIS PATIENTS WITH OR WITHOUT PRIOR INTOLERANCE OR INADEQUATE RESPONSE TO ADVANCED THERAPIES: RESULTS FROM THE ANTHEM-UC STU

May 01, 2026 |

By Edward V Loftus, Maria T. Abreu, Karen Chachu, Mary Ellen S. Frustaci

| Gastrointestinal Endoscopy

Also available on ScienceDirect

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Mary Ellen S.

Contact Mary Ellen S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Mary Ellen S. Frustaci

Get in touch with Mary Ellen S.

Actions

Is this you?

Articles

487 EFFICACY OF ICOTROKINRA, THE FIRST TARGETED ORAL PEPTIDE THAT SELECTIVELY BLOCKS THE INTERLEUKIN-23 RECEPTOR, IN ULCERATIVE COLITIS PATIENTS WITH OR WITHOUT PRIOR INTOLERANCE OR INADEQUATE RESPONSE TO ADVANCED THERAPIES: RESULTS FROM THE ANTHEM-UC STU

Actions

Is this you?

Get in touch with Mary Ellen S.